PEG-modified uricase

Details PEG-modified uricase PEG-modified uricase

2005-07-05

2005-07-05

Patterson, Jr., Charles L. (Department: 1652)

Chemistry: molecular biology and microbiology

Carrier-bound or immobilized enzyme or microbial cell;...

Enzyme or microbial cell is immobilized on or in an organic...

C435S191000, C435S188000, C424S900000

Reexamination Certificate

active

06913915

ABSTRACT:
The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome.

REFERENCES:
patent: 4062731 (1977-12-01), Snoke et al.
patent: 4064010 (1977-12-01), Harris et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4273874 (1981-06-01), Nakanishi et al.
patent: 4317878 (1982-03-01), Nakanishi et al.
patent: 4389485 (1983-06-01), Olivieri et al.
patent: 4394450 (1983-07-01), Brock et al.
patent: 4460683 (1984-07-01), Gloger et al.
patent: 4882280 (1989-11-01), Takashio et al.
patent: 4987076 (1991-01-01), Takashio et al.
patent: 5376545 (1994-12-01), Yagasaki et al.
patent: 5700674 (1997-12-01), Koyama et al.
patent: 5728562 (1998-03-01), Shigyo et al.
patent: 5801036 (1998-09-01), Koyama et al.
patent: 6576235 (2003-06-01), Williams et al.
patent: 6783965 (2004-08-01), Sherman et al.
patent: 2003/0166249 (2003-09-01), Williams et al.
Tsuju, J-I, et al. (1985) Int. J. Immunopharmac. 7(5), 725-730.
Caliceti, P., et al. (2201) Bioconjugate Chem. 12, 515-522.
Chen R. et al., Properties of two urate oxidases modified by the covalent attachment of poly(Ethylene Glycol), Biochim. Biophys. Act 660, 1981, pp 293-298.
Chua C.C. et al., “Use of polyethylene glycol-modified uricase (Peg-Uricase) to treat hyperuricemia in a patient with non-hodgkin lymphoma”,Ann Intern. Med,1988, 109, pp 114-117.
Davis, S. et al., “Hypouricaemic effect of polyethyleneglycol modified urate oxidase”The Lancet2, 1981, pp 281-283.
Delgado C. et al., “The uses and properties of PEG-linked proteins”,Crit. Rev. Ther. Drug Carrier Sys.,1992, 9, pp 249-304.
G. Masera et al.,Ann. Oncol8, 1996, 407.
Hande, K.R. et al., “Acute tumor lysis syndrome in patients with high-grade non-hodgkin's lymphoma”,Am J. Med.1993, 94, pp 133-139.
Jankovic M et al., “Urate-oxidase as hypouricemic agent in a case of acute tumor lysis syndrome”,Am J Pediatr. Hematol. Oncol.,1985, 7, pp 202-204.
Jones D.P. et al., Tumor lysis syndrome: pathogenesis and management,Pediatr Nephrol,1995, 9, pp 206-212.
Kalmkerian, G.P. et al., “Tumor lysis syndrome in small cell carcinoma and other solid tumors”,Am J. Med,1997, 103, pp 363-367.
Kelley, W.N. et al., Crystal-associated synovitis, Gout and hyperuricemia,R.L. Textbook of Rheumtology,5thedition, 1997, pp 1313-1351.
Lauter, CB et al., “Microbiologic assays and neurological toxicity during use of adenine arabinoside in humans”,Am J. Infect Dis,1976, 134, pp 75-79.
London M. et al., “Uricolytic activity of purified uricase in two human beings”,Science1957, 125, pp 937-938.
Lorigan, P.C. et al., “tumour lysis syndrome, case report and review of the literature”Ann Oncol,1996, 7, pp 631-636.
Masera G. et al., Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia,J Pediatrics,1982, 100, pp 152-155.
Monfardini, C et al., “A branched monomethoxypoly (ethylene glycol) for protein modification”,Bioconjungate Chem,1995, 6, pp 62-69.
Nishimara, H. et al., Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzyme activity,Enzyme,1981, 26, pp 49-53.
Oberling, F. et al., J.M. Nouvelle Presse Med 3, 1974 2026.
Parek et al., “Pharmacology ofescherichia coli-1-asparaginase polyethylene glycol adduct”,Anticancer Res.,1981, 1, pp 373-376.
Pui C. et al., “Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies”,Leukemia,1997, pp 1813-1816.
Savoca, K. et al., “Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase”,Int Archs. Allegy Appl. Immun. 1984,75, pp 58-67.
Tsuji, J. et al., “Studies on antigenicity of the polyethylene glycol(PEG)-modified uricase”,Int J Immunopharmac, 1985,7, pp 725-730.
Woloshuk et al., “Genetic transformation system for the aflatoxin-producing fungusaspergillus flavus”,Applied Environ. Microbiol,1989, 55, pp 86-90.
Wu, et al., “Hyperuricemia and urate nephropathy in urate oxidase-deficient mice”,Proc Natl Acad Sci USA,1994, 91, p 742-746.
Wu, et al., “Two independent mutational events in the loss of urate oxidase during hominoid evolution”,J. Mol Evol.1992, 34, pp 78-84.
Zalipsky, S et al., Polyethylene Glycol Chemistry:Biotechnical and biomedical applications,Topics in Applied Chemistry,Plenum Press, New York, 1992, pp 347-370.

Affiliated with

Also associated with

Rating

PEG-modified uricase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PEG-modified uricase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PEG-modified uricase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3376472